Cargando…

Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib

On the occasion of its recent approval for relapsed follicular lymphoma, we review the design and development of the pan-class I PI3K inhibitor copanlisib as a drug for the treatment of B-cell malignancies in comparison with other kinase inhibitors targeting B-cell-receptor signaling, in particular...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krause, Günter, Hassenrück, Floyd, Hallek, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109662/ https://www.ncbi.nlm.nih.gov/pubmed/30174412 http://dx.doi.org/10.2147/DDDT.S142406

Ejemplares similares

Relevant Cytokines in the B Cell Lymphoma Micro-Environment
por: Krause, Günter, et al.
Publicado: (2020)

The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression
por: Rohrbacher, Lisa, et al.
Publicado: (2021)

The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular carcinoma
por: Ye, Liangtao, et al.
Publicado: (2019)

The PI3Kδ Inhibitor Idelalisib Inhibits Homing in an in Vitro and in Vivo Model of B ALL
por: Adam, Etai, et al.
Publicado: (2017)

Update on the role of copanlisib in hematologic malignancies
por: Le, Thuy, et al.
Publicado: (2021)

The PI3Kδ inhibitor idelalisib impairs the function of human dendritic cells
por: Braun, Christiane, et al.
Publicado: (2021)

The PI3Kδ Inhibitor Idelalisib Diminishes Platelet Function and Shows Antithrombotic Potential
por: Barrachina, María N., et al.
Publicado: (2021)

Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma
por: Dreyling, M., et al.
Publicado: (2017)

Functional impact and molecular binding modes of drugs that target the PI3K isoform p110δ
por: Hassenrück, Floyd, et al.
Publicado: (2023)

Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
por: Ramanathan, Ramesh K., et al.
Publicado: (2020)

Sensitive Detection of the Natural Killer Cell-Mediated Cytotoxicity of Anti-CD20 Antibodies and Its Impairment by B-Cell Receptor Pathway Inhibitors
por: Hassenrück, Floyd, et al.
Publicado: (2018)

Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
por: Ramanathan, Ramesh K., et al.
Publicado: (2020)

A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2016)

PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors
por: Yahiaoui, Anella, et al.
Publicado: (2017)

Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives
por: Munoz, Javier, et al.
Publicado: (2021)

Model‐informed approach to support pediatric dosing for the pan‐PI3K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors
por: Morcos, Peter N., et al.
Publicado: (2023)

Discovery and SAR of Novel 2,3‐Dihydroimidazo[1,2‐c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80‐6946)
por: Scott, William J., et al.
Publicado: (2016)

Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts
por: Fang, Bin, et al.
Publicado: (2020)

The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo
por: Palazzo, Adam, et al.
Publicado: (2018)

A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib
por: Proudman, David, et al.
Publicado: (2022)

IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3K(δ) inhibitor idelalisib
por: Sandova, Veronika, et al.
Publicado: (2021)

Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia
por: Sharman, Jeff P., et al.
Publicado: (2019)

Combination of the PI3K inhibitor Idelalisib with the conventional cytostatics cytarabine and dexamethasone leads to changes in pathway activation that induce anti-proliferative effects in B lymphoblastic leukaemia cell lines
por: Sklarz, L.-M., et al.
Publicado: (2020)

Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas
por: Madanat, Yazan F, et al.
Publicado: (2016)

Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer “PantHER”
por: Keegan, Niamh M., et al.
Publicado: (2021)

Idelalisib for the Treatment of Chronic Lymphocytic Leukemia
por: Khan, Maliha, et al.
Publicado: (2014)

Idelalisib: a rare cause of enterocolitis
por: Balagoni, Harika, et al.
Publicado: (2016)

Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
por: Kutsch, Nadine, et al.
Publicado: (2022)

A Review of PI3K Inhibitors in B-Cell Malignancies
por: Cannon, Laura, et al.
Publicado: (2019)

Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma
por: Matasar, Matthew J., et al.
Publicado: (2021)

Pharmacokinetics of intravenous pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor [(14)C]copanlisib (BAY 80-6946) in a mass balance study in healthy male volunteers
por: Gerisch, Michael, et al.
Publicado: (2017)

Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells
por: Okabe, Seiichi, et al.
Publicado: (2016)

Copanlisib in the Treatment of Relapsed Follicular Lymphoma: Utility and Experience from the Clinic
por: Chauhan, Ayushi F, et al.
Publicado: (2021)

Targeting neoplastic B cells and harnessing microenvironment: the “double face” of ibrutinib and idelalisib
por: Maffei, Rossana, et al.
Publicado: (2015)

A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial
por: Grunenberg, Alexander, et al.
Publicado: (2021)

Crystal structure of idelalisib tert-butanol monosolvate dihydrate
por: Nerdinger, Sven, et al.
Publicado: (2019)

The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab
por: Kreuzer, Karl-Anton, et al.
Publicado: (2019)

Idelalisib: The First-in-Class Phosphatidylinositol 3-Kinase Inhibitor for Relapsed CLL, SLL, and Indolent NHL
por: Forcello, Nicholas, et al.
Publicado: (2014)

BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia
por: Falchi, Lorenzo, et al.
Publicado: (2016)

Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial
por: Ghia, Paolo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c6dtubcjs6jjthimatelksk6nk